#ORPH Open Orphan Plc – $13.4m Influenza HCS contract win December 10, 2021 – Posted in: Blog, Open Orphan (ORPH)

(AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO , a subsidiary of Open Orphan plc, has signed a $13.4m contract with a US-based biotechnology company to test its novel antiviral candidate using the hVIVO Influenza Human Challenge Study Model.   The study is expected to commence in H2 2022 and will be conducted at hVIVO’s state-of-the-art quarantine facilities in…

Continue reading